单次高剂量率近距离放疗联合大分割外照射可提高中高危前列腺癌生化无病生存率
该研究前瞻性收集95例中高危局限性前列腺癌患者,接受单次12.5Gy高剂量率近距离放疗推量后联合37.5Gy/15次大分割外照射。中位随访65个月,5年生化无病生存率为80.5%(95%CI 72.8-89.0),多因素分析仅初始PSA预测生化无病生存较差。
要点
- 单次HDR近距离放疗推量联合大分割EBRT方案可行,5年生化DFS达80.5%。
- 队列以高危患者为主(64%),97%接受新辅助雄激素剥夺治疗。
- 多因素分析仅初始PSA(HR 1.03)与生化DFS较差相关。
核心结论
- 外照射联合单次HDR近距离放疗推量在 predominantly 高危前列腺癌队列中取得良好的生化控制。
研究设计与样本
- 前瞻性收集2008至2010年95例中高危局限性前列腺癌患者,接受单次12.5Gy HDR推量后37.5Gy/15次/3周EBRT。
- 61/95(64%)为高危,34/95(36%)为中危;92/95(97%)接受新辅助ADT。
- 采用ASTRO定义生化失败(PSA较最低值升高2μg/L)。
主要发现
- 中位随访65个月(范围18-88),5年生化DFS为80.5%(95%CI 72.8-89.0)。
- 多因素分析中仅初始PSA(HR 1.03;CI 1.00-1.05,p=0.03)预测生化DFS较差。
- 分析模型纳入临床分期、初始PSA、ADT持续时间、Gleason评分、风险分组、前列腺体积、D90和V100。
关键数值与推荐
- HDR推量剂量12.5Gy单次,EBRT剂量37.5Gy/15次/3周。
- 生化失败定义为PSA较最低值升高2μg/L(ASTRO定义)。
临床怎么用
- 对于中高危局限性前列腺癌,可考虑单次HDR推量联合大分割EBRT作为剂量递增策略。
- 治疗决策时需结合初始PSA水平评估生化复发风险。
局限性
- 样本量95例,非随机对照设计。
- 97%患者接受新辅助ADT,辅助激素治疗由临床医生决定,可能影响生化结局解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dose escalation has been shown to improve biochemical outcome in localised prostate cancer. An HDR brachytherapy boost is an effective strategy for dose escalation, since it exploits the low α/β ratio in prostate cancer, allowing the delivery of a high biological dose to the tumour. We sought to evaluate the biochemical disease free survival in patients with intermediate and high risk localised prostate cancer treated with EBRT plus HDR brachytherapy as a boost, in our institution. PATIENTS AND METHODS: Biochemical outcome was collected prospectively in 95 patients treated from 2008 to 2010, with an HDR boost of 12.5Gy followed by EBRT delivered as 37.5Gy in 15 fractions over 3weeks. The ASTRO definition of biochemical failure (2μg/L above PSA nadir) was used as the outcome measure. 61/95 (64%) were classified as high risk (stage>T2b or PSA>20μg/L or Gleason score>7) while 34/95 (36%) were intermediate risk. 92/95 (97%) patients received neoadjuvant androgen deprivation therapy (ADT). Adjuvant hormone therapy was at the discretion of the treating clinician. RESULTS: The median follow-up for the cohort was 65months (range, 18-88) with a 5-year biochemical DFS of 80.5% (95% Confidence Interval [CI]: 72.8-89.0). The prognostic factors used in the analysis model were: clinical stage, presenting PSA, duration of ADT, Gleason score, risk category, prostate volume, D90 and V100. Only presenting PSA (HR 1.03; CI 1.00-1.05, p=0.03) predicted for a poorer biochemical DFS on multivariate analysis. CONCLUSION: These data confirm that EBRT plus a single-fraction HDR brachytherapy boost achieves good biochemical control in a cohort of predominantly high risk patients.
引用
- Joseph N, Taylor C, O'Hara C, et al. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Radiother Oncol. 2016. PMID: 28029404. doi:10.1016/j.radonc.2016.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。